952 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Bought by Bayesian Capital Management LP

Bayesian Capital Management LP purchased a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 952 shares of the biopharmaceutical company’s stock, valued at approximately $678,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Principal Financial Group Inc. boosted its position in shares of Regeneron Pharmaceuticals by 1.7% during the 3rd quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock worth $181,961,000 after acquiring an additional 2,828 shares in the last quarter. Nordea Investment Management AB boosted its holdings in shares of Regeneron Pharmaceuticals by 23.6% in the 4th quarter. Nordea Investment Management AB now owns 42,667 shares of the biopharmaceutical company’s stock valued at $30,160,000 after purchasing an additional 8,135 shares in the last quarter. Diversified Trust Co boosted its holdings in shares of Regeneron Pharmaceuticals by 93.0% in the 4th quarter. Diversified Trust Co now owns 2,330 shares of the biopharmaceutical company’s stock valued at $1,660,000 after purchasing an additional 1,123 shares in the last quarter. Range Financial Group LLC bought a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $220,000. Finally, First Hawaiian Bank raised its holdings in shares of Regeneron Pharmaceuticals by 18.8% during the 4th quarter. First Hawaiian Bank now owns 2,995 shares of the biopharmaceutical company’s stock worth $2,133,000 after buying an additional 474 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 7.5 %

REGN opened at $558.52 on Wednesday. The company has a fifty day moving average price of $621.54 and a two-hundred day moving average price of $703.65. Regeneron Pharmaceuticals, Inc. has a 1-year low of $525.99 and a 1-year high of $1,211.20. The company has a market cap of $61.06 billion, a P/E ratio of 14.59, a price-to-earnings-growth ratio of 2.34 and a beta of 0.43. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts’ consensus estimates of $8.83 by ($0.61). The firm had revenue of $3.03 billion during the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business’s quarterly revenue was down 3.7% on a year-over-year basis. During the same period in the previous year, the firm earned $9.55 earnings per share. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.63%. The ex-dividend date is Tuesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is currently 8.96%.

Analyst Ratings Changes

A number of research analysts have issued reports on REGN shares. Sanford C. Bernstein decreased their target price on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 7th. Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. Wells Fargo & Company dropped their price objective on shares of Regeneron Pharmaceuticals from $750.00 to $700.00 and set an “overweight” rating for the company in a research note on Wednesday, April 30th. Citigroup decreased their target price on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Finally, UBS Group dropped their price target on Regeneron Pharmaceuticals from $768.00 to $633.00 and set a “neutral” rating for the company in a research note on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, eighteen have issued a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $892.60.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.